BALONEY! Says nothing about “all cancers” you made that up. “Large scale-up” likely refers to just GBM beyond the UK, but they are nebulous about it, as usual.
Here’s a deep think question; If GBM cells provide so many different antigens for DCVAX to program the immune system, why wouldn’t the therapy naturally already cover other kinds of cancer cells?
Market Data 
Markets 
AI
